Neurohypophyseal response to fluid resuscitation with hypertonic saline during septic shock in rats.
Septic shock is a serious condition with a consequent drop in blood pressure and inadequate tissue perfusion. Small-volume resuscitation with hypertonic saline (HS) has been proposed to restore physiological haemodynamics during haemorrhagic and endotoxic shock. In the present study, we sought to determine the effects produced by an HS infusion in rats subjected to caecal ligation and perforation (CLP). Male Wistar rats were randomly grouped and submitted to either CLP or sham surgery. Either HS (7.5% NaCl, 4 ml kg(-1) i.v.) or isotonic saline (IS; 0.9% NaCl, 4 ml kg(-1) i.v.) was administered 6 h after CLP. Recordings of mean arterial pressure and heart rate were made during this protocol. Moreover, measurements of electrolyte, vasopressin and oxytocin secretion were analysed after either the HS or the IS treatment. Six hours after CLP, we observed a characteristic decrease in mean arterial pressure that occurs after CLP. The HS infusion in these rats produced a transient elevation of the plasma sodium concentration and osmolality and increased plasma vasopressin and oxytocin levels. Moreover, the HS infusion could restore the mean arterial pressure after CLP, which was completely blunted by the previous injection of the vasopressin but not the oxytocin antagonist. The present study demonstrated that rats subjected to CLP and an infusion of hypertonic saline respond with secretion of neurohypophyseal hormones and a transient increase in blood pressure mediated by the V(1) receptor.
Department of Physiology, Institute of Biomedical Science, Federal University of Alfenas – MG, Alfenas, Minas Gerais, Brazil.
Michael Brian
MB
Santiago
Alexandre Antonio
AA
Vieira
Lucila L K
LL
Elias
José Antunes
JA
Rodrigues
Alexandre
A
Giusti-Paiva
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D062186:Arterial Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D005440:Fluid Therapy / Q000379:methods*; D006339:Heart Rate; D006706:Homeostasis; D006727:Hormone Antagonists / Q000494:pharmacology; D007262:Infusions, Intravenous; D008297:Male; D009994:Osmolar Concentration; D010121:Oxytocin / Q000097:blood; D010904:Pituitary Gland, Posterior / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000378:metabolism; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage*; D012772:Shock, Septic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D012964:Sodium / Q000097:blood; D013997:Time Factors; D014667:Vasopressins / Q000097:blood; D014882:Water-Electrolyte Balance
D065092:Antidiuretic Hormone Receptor Antagonists; D006727:Hormone Antagonists; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D012462:Saline Solution, Hypertonic; D014667:Vasopressins; D010121:Oxytocin; D012964:Sodium